Natural Killer Cells Alternative Cancer Treatment And Advanced Natural Cancer Treatment Aor Stage 4 Colon Cancer

Immunotherapy Strengthens Fight Against Stage 4 Colon and Stage 4 Cancer with Alternative Cancer Treatment and Natural Cancer Treatment that Matter

Immunotherapy is undisputedly an innovative premier medical strategy that relies on the human immune system to conquer disease. Theoretically over the last 30 odd years, extensive research conducted by teams of physicians and scientists has proven that this venue is clinically successful for a wide range of diseases. Advances in adoptive immunotherapy, which concentrates on the expansion and infusion of specific disease-fighting white blood cells in patients, have boosted this science to peak performance in terms of being an effective treatment for viral diseases, colon cancer, and even stage 4 cancer types.

We can expect, taking into consideration the undeniable results and continued advances, the importance of immunotherapy to grow exponentially - particularly as it applies to late stage colon and other stage 4 cancers. To date, stage 4 colon cancer is not much more than chemo and radiation and the statistics are so grim - renowned care providers do not dare report survival data beyond the first couple of years as it is more sobering than promising.

New immunotherapy treatments, however, are bringing new hope as they deliver a key part of the treatment puzzle - along with better results and quality of life for patients.

Natural Killer and Natural Killer T Cells are Depressed in Stage 4 Colon Cancer Patients the Need For Alternative Cancer Treatment and Natural Cancer Treatment

In a concentrated study¹ of 102 colorectal cancer patients undergoing resections; 18 of them suffered recurrences within two years of surgery. In all 18, there was significant evidence of "significantly lower preoperative NK cytotoxicity than disease-free patients." Low preoperative NK cytotoxicity was predictive of recurrence in this grouping of patients.¹

Subsequently, in an added study² with nearly 200 subjects, 49 of which suffered with colon cancer in addition to 149 healthy controls, it was advised that Natural Killer levels in colon cancer patients were significantly lower than those of the healthy control group.

For the record, it has been shown³ that untreated patients with colon cancer have suppressed Natural Killer and Lymphokine-activated killer cells - particularly in late stage patients. These patients were also found to have unremarkable interferon-gamma producing activities.

NK cell activity serves as a favorable prognostic factor for distant metastasis following surgery for colon cancer. In a related study⁴ with 140 colon cancer patients in curatively operated stage I-III diseases, preoperative NK cell activity of 20 percent or less correlated with abjectly poor survival. This lower NK activity was also in sync with distant metastases, while attenuated NK cell activity was a reasonable parameter for predicting distant metastasis following curative surgery.

Overall evidence⁵ suggests that pretreatment levels of NK cytotoxicity in patients are significantly related to overall survival, progression-free survival, and response rate. Furthermore, it has also been observed that colon cancer patients who are 6 to 12 months post tumor resection, have demonstrated a rise in spontaneous, antibody-induced, and PHA-induced cytotoxicity levels - immensely higher than those found in age-matched controls of healthy individuals.

Inexplicably, conventional medicine has seemingly ignored such immunotherapy methods ... until now.

Astounding Progress in Treating Stage 4 Colon Cancer and Other Stage 4 Cancers with Immunotherapy Breakthrough Alternative Cancer Treatment and Natural Caner Treatment

In recent months a distinguished staff of researchers have declared successful the clinical use of natural killer cells (NKs) and natural killer T cells (NKTs) in treating patients with various malignancies.8,9 While NKs and NKTs are routinely circulating in the body in wee amounts, they possess the ability to identify and destroy both tumor cells and virally infected cells, and are a major radical defense of our immune system. Without reservation, patients stricken with colon cancer and stage 4 cancers are often found to be deficient in production of these warrior- like cells. Over the last couple of decades, a mass of studies have described NK dysfunction in colon cancer patients.10-12

Specifically, NKs from these patients show an anemic ability to destroy tumor cells in laboratory conditions than NKs from healthy patients.10-12 NKs from later stage patients were deemed dramatically more dysfunctional compared to early stage patients with no metastases.10,11 Further, NKs from patients with more advanced disease had an impaired response to interferon, a major growth factor for NK cells.10 T lymphocytes from these patients also do not respond well to stimulatory factors.12 The amount and function of NKT cells have also been under review in colon cancer patients.13 NKT numbers in these patients were flagged as reduced compared to healthy controls and patients with other cancer types; further, NKTs in these patients were less responsive to short-term stimulation, yet were still capable of substantial expansion.13 Responsible research cumulatively cites that colon cancer patients experience an immune suppression that accelerates as disease progresses. However, cells with anti-tumor activity can certainly be expanded from these patients for valuable use in clinical immunotherapy regimens.

The expansion of natural killer cells is a completely different approach in both process and effect than is taking a product or providing an intravenous nutrient or substance to increase NK cells in the patient. Such methods are far inferior to the targeted, expansion method described above.

Natural Killer and Natural Killer T Cells are Depressed in Stage 4 Colon Cancer Patients Research For Alternative Cancer Treatment and Natural Cancer Treatment Options

In a study¹ of 102 colorectal cancer patients undergoing resections; 18 of them underwent recurrences within two years of surgery. In all 18, there was significant evidence of "significantly lower preoperative NK cytotoxicity than observed in disease-free patients." Low preoperative NK cytotoxicity was predictive of recurrence in this melange of patients.¹

In yet another study conducted² with nearly 200 subjects, 49 of which suffered with colon cancer in addition to 149 healthy controls, it was verified that Natural Killer levels in colon cancer patients were significantly lower than those of the healthy control group.

For all intents and purposes, it has been shown³ that untreated patients with colon cancer have suppressed Natural Killer and Lymphokine-activated killer cells - particularly in late stage patients. These individuals were also believed to have compromised interferon-gamma producing activities.

NK cell activity continues to be a solid prognostic factor for distant metastasis following surgery for colon cancer. In a related study⁴ with 140 colon cancer patients in curatively operated stage I-III diseases, preoperative NK cell activity of 20 percent or less correlated with poor survival. This lower NK activity was also associated with distant metastases, while attenuated NK cell activity was a valued parameter for predicting distant metastasis following curative surgery.

Added evidence⁵ suggests that pretreatment levels of NK cytotoxicity in patients are significantly related to overall survival, progression-free survival, and response rate. To be clear, it has also been observed that colon cancer patients who are 6 to 12 months beyond tumor resection, have shown a rise in spontaneous, antibody-induced, and PHA-induced cytotoxicity levels - significantly higher than those found in age-matched controls of healthy individuals.

This data begs the question why are NK cells and immune system considered vastly more important to conventional cancer treatment protocols? It was questions like this one that led Envita to develop a proprietary new treatment.

Envita Leads the Field in Stage 4 Colon Cancer and Stage 4 Cancer Immunotherapy Using Alternative Cancer Treatment and Natural Cancer Treatment

Volumes of published materials have demonstrated the effects of adoptive immune therapy in cancer patients. Envita's established medical team assessed the most reliable of these studies and focused on the strengths and weaknesses of each. Their notations established a protocol that incorporates only the best procedures for the expansion and application of cells as a powerful immunotherapy. Our protocols rely on the most recent published research in the field, from several of the most prestigious hospitals and universities in our nation and around the globe. Essentially, our treatment has been specially designed to deal specifically with colon cancer and stage 4 cancer patients' immune systems.

Envita's Two-fold for Stage 4 Colon Cancer and Stage 4 Cancer Immunotherapy The Need For Alternative Cancer Treatment and Natural Cancer Treatment

Envita Natural Medical Center in its Mexico office is currently using NK cells and CTLs as immunotherapy treatment for colon cancer and stage 4 cancer patients. Envita's proprietary immune therapy vaccine is registered as AAIT (for autologous adoptive immune therapy,) and there are 4 major cell types involved - the great majority being natural killer cells and T cells. The types of cells are incorporated in Envita's treatment are as follows: natural killer cells, natural killer T cells, cytokine-induced killer cells, and cytotoxic T lymphocytes.

The vaccine(s) is designed by growing a patient’s own antitumor immune cells into countless billions. These cells are then targeted for activation markers and tested for their ability to marginalize colon cancer and other stage 4 cancer cells in the lab, then re-infused into the patient.

Enhancing the immune system is a major boon to fighting colon cancer as well as other cancers, but this vaccine-driven immunotherapy routine may be improved upon through subtraction. In other words, we can improve results by not only energizing critical components of the immune system, but simultaneously depleting it of negative factors that impede its functionality. Depleting such negative factors is critical to a patient's success.

It is undeniable that cancer cells effect the release of T-regulatory cells, or "negative T cells." The numbers of these cells correlate directly with specific cancer stages - respective to each cancer type. Note: the more advanced the cancer, the higher the T-regulatory cells. These cells barricade your body’s systemic ability to fight. The immune system is the primary and last defense against cancer.

Naturally, by intervening and working to deplete these cells along with other vital enzymes that block critical immune system, cancer cell-killing action will be expedited exponentially. Consider that your immune system is targeted and, at the ready, yet something in your body suddenly activates the brakes. This is reliably what most advanced colon cancer and stage 4 cancer patients experience regarding to high regulatory T cells. Envita's immunotherapy treatment protocols tailor a targeted vaccine by using the body's most powerful cancer killers, but also depletes that portion of the immune system that inhibits the body from functioning efficiently in such regard.

Pointedly, there is no treatment (conventional or alternative) that can be effective in the later stages of cancer if these negative T-cells are not overwhelmingly down-regulated.

Envita’s AAIT, unlike other available immunotherapy treatments, can be used as a free agent. AAIT can also be administered in conjunction with other therapies that will serve to enhance the effects of cells once they are in the patient. This is a stellar improvement over many of the published studies in the scientific literature. Envita’s AAIT therapy is not just calculated to expand cells in the laboratory; the ultimate goal is to ultimately expand them and keep them activated after they are infused back into the body. Making AAIT the next important element to geared to battle colon cancer and supplement stage 4 cancer therapy.

AAIT Immunology Available for Stage 4 Colon cancer and Stage 4 Cancer Patients at Envita Mexico Alternative Cancer Treatment and Natural Cancer Treatment that Matters

Envita Natural Medical Center is currently distributing NK, NKT, and T lymphocytes as supportive immunotherapy for our cancer patients. Envita’s therapy is actually titled AAIT, and increases a patient’s own antitumor immune cells into the billions over a course of weeks. These cells are monitored for activation markers, evaluated for their ability to dessimate cancer cells in the laboratory, and then ultimately re-infused into the patient. Heralded by scientific research and clinical results, Enivta's AAIT immunotherapy proudly presents a potent option for cancer patients who are dedicated to battling colon and other stage 4 cancers while maintaining an intact immune system. Envita administers only superior combinations of conventional and alternative cancer treatment bolstered by advanced natural cancer treatment to help patients get healthier and improve their overall quality of life.

1. Tartter PI, Steinberg B, Barron DM, Martinelli G. The prognostic significance of natural killer cytotoxicity in patients with colorectal cancer. Arch Surg. 1987 Nov;122(11):1264-8.

2. Balch CM, Tilden AB, Dougherty PA, Cloud GA. Depressed levels of granular lymphocytes with natural killer (NK) cell function in 247 cancer patients. Ann Surg. 1983 Aug;198(2):192-9.

3. Kondo E, Koda K, Takiguchi N, Oda K, Seike K, Ishizuka M, Miyazaki M. Preoperative natural killer cell activity as a prognostic factor for distant metastasis following surgery for colon cancer. Dig Surg. 2003;20(5):445-51. Epub 2003 Jul 31.

3. Matsunaga H, Kuwahara Y, Kusugami K, Morise K, Shimokata K. Natural killer, lymphokine-activated killer and interferon-gamma producing activities of peripheral blood- and regional lymph node-mononuclear cells in 23 cases of colorectal cancer. Gastroenterol Jpn. 1988 Oct; 23(5):527-33.

4. Kondo E, Koda K, Takiguchi N, Oda K, Seike K, Ishizuka M, Miyazaki M. Preoperative natural killer cell activity as a prognostic factor for distant metastasis following surgery for colon cancer. Dig Surg. 2003;20(5):445-51. Epub 2003 Jul 31.

5. Liljefors M, Nilsson B, Hjelm Skog AL, Ragnhammar P, Mellstedt H, Frodin JE. Natural killer (NK) cell function is a strong prognostic factor in colorectal carcinoma patients treated with the monoclonal antibody 17-1A. Int J Cancer. 2003 Jul 10;105(5):717-23.

6. Waller CA, Gill PG, MacLennan IC. Enhancement of lymphocyte-mediated cytotoxicity after tumor resection in patients with colorectal cancer. J Natl Cancer Inst. 1980 Aug;65(2):223-30.

Article Source: http://www.compensationsecrets.co.uk/